NMN and NR: Compounded vs. Branded, What the Evidence Actually Shows

Why NAD+ Precursors Matter Clinically

NAD+ (nicotinamide adenine dinucleotide) declines roughly 50% between age 20 and 60 in human tissues. [1] That decline correlates with reduced mitochondrial efficiency, impaired DNA repair, and dysregulated sirtuin activity. Oral precursors such as NMN and NR are the two most studied routes to raise NAD+ without intravenous infusion.

The NAD+ Biosynthesis Pathway

NMN is phosphorylated directly to NAD+ via NMN adenylyltransferases (NMNATs). NR is converted to NMN first, then to NAD+. One extra enzymatic step does not automatically make NR inferior, conversion efficiency depends on tissue-specific expression of NRK1/NRK2 kinases, which vary by organ. [2]

Nicotinic acid (niacin) and nicotinamide are older, cheaper precursors, but both produce flushing and, at pharmacologic doses, hepatotoxicity risks that NMN and NR largely avoid at therapeutic doses. [3]

Tissue Selectivity Considerations

A 2022 mouse study published in Cell Metabolism found NMN preferentially raised NAD+ in skeletal muscle and liver, while NR showed broader distribution including brain tissue. [4] Direct head-to-head human tissue-distribution data are not yet available, so clinician guidance on selecting one over the other for specific organ targets remains inference-based.

Branded NMN and NR: Regulatory Status and Trial Data

Branded products occupy a contested regulatory space. They are not FDA-approved drugs, but several carry more clinical evidence than most compounded preparations.

FDA's 2022 NMN Exclusion Decision

In November 2022, the FDA issued warning letters stating that NMN cannot be marketed as a dietary supplement because it was under investigation as a new drug before it was marketed as a supplement. [5] This is a critical distinction. It does not mean NMN is unsafe. It means the Dietary Supplement Health and Education Act (DSHEA) pathway is closed for NMN unless the FDA changes course. Branded NMN companies such as Alive By Science continue selling under ambiguity; enforcement remains inconsistent as of mid-2025.

NR (nicotinamide riboside) does not carry the same exclusion. ChromaDex's patented Niagen form of NR has GRAS (Generally Recognized as Safe) status and an accepted New Dietary Ingredient (NDI) notification. [6]

Tru Niagen (NR) Human Trial Data

The Elysium Health BASIS trial (N=120, randomized, double-blind, placebo-controlled, 8 weeks) tested 250 mg NR + 50 mg pterostilbene daily. Whole-blood NAD+ rose 40% in the low-dose arm and 90% in the high-dose arm (500 mg NR + 100 mg pterostilbene) vs. Baseline. [7] Adverse events were comparable to placebo.

A separate ChromaDex-funded trial (N=140, 8 weeks) reported that 300 mg/day Tru Niagen raised blood NAD+ by approximately 51% vs. 0% for placebo (P<0.001). [8] Neither trial has yet demonstrated a clinical endpoint such as reduced cardiovascular events or improved cognition in humans.

Yoshino et al. 2021, The Key NMN Human Trial

The most rigorous human NMN study to date enrolled 25 postmenopausal women with prediabetes or obesity (mean BMI 32.5 kg/m²). Yoshino et al., published in Science (2021), randomly assigned participants to 250 mg/day oral NMN or placebo for 10 weeks. [9]

NMN supplementation significantly improved skeletal-muscle insulin sensitivity as measured by a hyperinsulinemic-euglycemic clamp (a gold-standard technique). Muscle gene expression analysis showed upregulation of pathways involved in glucose metabolism and remodeling. No significant changes in body weight, blood pressure, or circulating lipids were observed. The authors noted: "These results suggest that oral NMN administration is safe and sufficiently bioavailable to exert pharmacological activity in postmenopausal women with prediabetes or obesity." [9]

This single trial used a dose of 250 mg/day. Extrapolating to the 500 to 1,000 mg doses found in many compounded formulations lacks supporting human evidence.

Compounded NMN: How It Is Made and What Risks Exist

Compounding pharmacies prepare NMN when a licensed prescriber writes an order. That simple fact changes the regulatory calculus entirely compared to buying a branded supplement off Amazon.

USP Oversight and the Missing NMN Monograph

Compounded preparations must comply with USP General Chapter 795 (nonsterile) or 797 (sterile). [10] These chapters govern facility standards, beyond-use dating, and testing for contamination. The critical gap: no USP monograph exists specifically for NMN as of mid-2025. Without a monograph, the compounding pharmacy sets its own purity specification, typically accepting certificate-of-analysis (CoA) data from its API supplier.

API (active pharmaceutical ingredient) sourcing for NMN is predominantly Chinese manufacturers. Purity claims of 99%+ are common on CoAs, but independent third-party verification by a US-based ISO 17025-accredited lab is not uniformly required or provided. This is not a theoretical concern. A 2021 analysis of 22 commercially available NMN supplements found 10 contained less than 50% of the labeled NMN content. [11]

Sublingual vs. Oral Compounded NMN

Some compounding pharmacies offer sublingual troches or drops on the premise that bypassing first-pass metabolism improves bioavailability. Direct human pharmacokinetic data comparing sublingual to oral NMN are sparse. A small crossover study (N=10) published in Nutrients (2022) found oral NMN at 250 mg raised plasma NMN detectably within 2 to 3 hours, with peak NAD+ metabolite appearance at 6 hours. [12] The study did not include a sublingual arm. Sublingual advantages remain plausible but unconfirmed in controlled human trials.

Prescription-Only Compounded NMN and Off-Label Use

Because the FDA's drug-investigation exclusion applies to NMN, compounding it as a prescription medication positions it within a legal framework, even if it grays regulatory lines. Physicians at telehealth platforms prescribe compounded NMN off-label for:

• Age-related NAD+ decline (no FDA-approved indication)
• Exercise performance and muscle recovery
• Insulin resistance adjunct therapy
• Potential neuroprotection (based on animal data only)

A practical prescribing framework used at HealthRX considers four criteria before recommending compounded vs. Branded: (1) documented third-party purity from an ISO 17025-accredited lab, (2) prescriber ability to adjust dose beyond OTC options, (3) patient cost sensitivity, and (4) whether the clinical goal aligns with a trial-tested dose and population. Branded NR wins on points 1 and 4. Compounded NMN wins on point 2. Neither has strong footing on translating surrogate endpoints to hard clinical outcomes.

Head-to-Head Comparison: NMN vs. NR in Humans

The question patients ask most is simple: which one actually works better?

Blood NAD+ Elevation

Both NMN and NR reliably raise blood NAD+ in humans. Dollerup et al. (2018, N=40, randomized, double-blind, 12 weeks) found 1,000 mg/day NR raised whole-blood NAD+ by 60% vs. Placebo with no improvement in insulin sensitivity, VO2 max, or body composition in healthy obese men. [13] Yoshino 2021 found 250 mg/day NMN improved insulin sensitivity in prediabetic women without similar metabolic improvements in body weight. The different outcomes across these trials may reflect population selection rather than the molecule itself.

Dose Comparison Across Published Trials

| Study | Compound | Dose | Duration | N | Primary Outcome | |---|---|---|---|---|---| | Yoshino et al. 2021 [9] | NMN | 250 mg/day | 10 weeks | 25 | Improved insulin sensitivity | | Dollerup et al. 2018 [13] | NR | 1,000 mg/day | 12 weeks | 40 | No metabolic improvement | | Elysium BASIS 2017 [7] | NR | 250 mg/day | 8 weeks | 120 | +40% blood NAD+ | | ChromaDex/Tru Niagen 2023 [8] | NR | 300 mg/day | 8 weeks | 140 | +51% blood NAD+ | | Martens et al. 2018 [14] | NR | 500 mg twice daily | 6 weeks | 30 | Reduced arterial stiffness in older adults |

Martens et al. (2018, Nature Communications, N=30) found 1,000 mg/day NR for 6 weeks reduced aortic stiffness and systolic blood pressure in older adults, with a mean systolic reduction of 3.9 mmHg vs. Placebo (P<0.05). [14] That is a meaningful signal for cardiovascular risk reduction, though the trial was small.

Why the Outcomes Diverge

Yoshino's improvement in insulin sensitivity but not weight is biologically coherent. NAD+-dependent sirtuin 1 (SIRT1) activation in skeletal muscle improves glucose transporter 4 (GLUT4) expression. That pathway is largely independent of adipose tissue lipolysis, so weight neutrality alongside metabolic improvement is expected. Expecting NMN to be a weight-loss drug misreads the mechanism.

Purity, Stability, and Storage Differences

Branded NR products from ChromaDex are manufactured under GMP (Good Manufacturing Practice) conditions with published stability data. Tru Niagen has a shelf life of 24 months with standard storage. [15] NMN is hygroscopic and degrades faster than NR when exposed to humidity; proper compounding requires desiccant packaging and cool storage, which not all pharmacies guarantee.

Third-party certification programs such as NSF International or USP Verified exist for branded supplements. As of this writing, no major branded NMN product holds an NSF or USP Verified mark, though several NR products do. Compounded NMN holds none of these certifications by definition, since it is a pharmacy preparation, not a supplement.

Cost Analysis

Compounded NMN at 250 mg/day costs approximately $60, $120 per 30-day supply depending on pharmacy, dose, and formulation. Branded NR (Tru Niagen 300 mg) retails at approximately $40, $60 per 30 days. A 500 mg/day compounded NMN supply may cost $100, $180/month, with no clinical trial supporting that dose over 250 mg in humans.

Insurance does not cover either option. Neither NMN nor NR has an FDA-approved indication, so no CPT code applies.

Safety Profile: What the Trials Report

Both molecules appear safe at studied doses. The most comprehensive NMN safety review to date (Igarashi et al., 2022, npj Aging, N=30, 12-week RCT) tested 250 mg/day NMN in healthy older men aged 65 and found no serious adverse events, no changes in liver enzymes, renal function, or complete blood count. [16] Minor GI discomfort (nausea, loose stool) occurred in 3 of 15 NMN participants vs. 1 of 15 placebo, a non-significant difference.

One theoretical safety concern: NAD+ precursors upregulate CD38, an enzyme that degrades NAD+. Chronic supplementation could theoretically create a compensatory upregulation that limits long-term benefit. This has been observed in cell culture but not confirmed in human trials. [17]

Patients with a history of hormone-receptor-positive cancers should discuss NAD+ precursor use with their oncologist before starting. Sirtuin activation has pro-survival effects in some cancer cell lines. The clinical relevance in humans is unresolved. [18]

Who Should Consider Each Option

Candidates for Branded NR (Tru Niagen or equivalent)

Patients who prioritize the following may do better with a branded NR:

• Documented third-party purity (NSF, Informed Sport)
• Proven manufacturing GMP with stability data
• Consistency with the most voluminous human trial dataset
• Lower monthly cost at equivalent NAD+-raising doses

Candidates for Compounded NMN

Patients or prescribers who may favor compounded NMN:

• Need for doses above 300 mg (though clinical justification is limited)
• Preference for sublingual delivery (limited evidence base)
• Physician oversight as part of a broader longevity protocol
• Documented pharmaceutical-grade CoA from the dispensing pharmacy

When to Avoid Both

Patients with active hepatic disease, those on niacin-based lipid therapies, or those receiving chemotherapy should not start NAD+ precursors without specialist clearance. The dose-response curve above 500 mg/day in humans has not been characterized.

Regulatory Outlook Through 2026

The FDA's drug-investigation exclusion for NMN created market confusion, not market exit. Several companies have submitted Citizen Petitions requesting the FDA reconsider this classification. A final FDA decision could either legitimize NMN as a dietary supplement or formally classify it as a drug requiring an approved NDA. That decision will materially affect compounding access. Clinicians should track the FDA's NDI notification database and the official guidance page at fda.gov for updates. [5]

NR's regulatory path is cleaner. Its GRAS status and accepted NDI mean it is unlikely to face the same exclusion absent new drug investigation filings.